fp 83 has been researched along with Neoplasms in 3 studies
FP 83: structure given in first source
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the treatment effect reducing cancer-related multiple breakthrough pain (BTP) between immediate release morphine sulfate (IRMS) and flurbiprofen axetil." | 7.79 | Intravenous flurbiprofen axetil to relieve cancer-related multiple breakthrough pain: a clinical study. ( Cheng, X; Hao, J; Shao, Y; Wang, K; Yan, Z, 2013) |
| "To compare the treatment effect reducing cancer-related multiple breakthrough pain (BTP) between immediate release morphine sulfate (IRMS) and flurbiprofen axetil." | 3.79 | Intravenous flurbiprofen axetil to relieve cancer-related multiple breakthrough pain: a clinical study. ( Cheng, X; Hao, J; Shao, Y; Wang, K; Yan, Z, 2013) |
| "A total of 120 cancer patients was randomly divided into two groups, 60 patients took orally morphine sulfate sustained-release tablets in group A, and another 60 patients receiving the combination treatment of intravenous flurbiprofen axetil and opioid drugs in group B." | 2.79 | Intravenous flurbiprofen axetil enhances analgesic effect of opioids in patients with refractory cancer pain by increasing plasma β-endorphin. ( Gao, JF; Ou, WL; Rao, ZG; Wang, J; Wang, ZG; Wu, TT; Yang, B; Yao, GQ; Zhang, BC, 2014) |
| "Thirty-seven cases of cancer patients who had bad effect from anaesthetic drugs were received administration of intravenous flurbiprofen axetil with dose of 50 mg/5 ml/day." | 1.35 | Intravenous flurbiprofen axetil can increase analgesic effect in refractory cancer pain. ( Chen, Z; Du, Y; Gu, K; Hao, J; Ning, J; Pan, Y; Sun, G; Wu, H, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, TT | 1 |
| Wang, ZG | 1 |
| Ou, WL | 1 |
| Wang, J | 1 |
| Yao, GQ | 1 |
| Yang, B | 1 |
| Rao, ZG | 1 |
| Gao, JF | 1 |
| Zhang, BC | 1 |
| Wu, H | 1 |
| Chen, Z | 1 |
| Sun, G | 1 |
| Gu, K | 1 |
| Pan, Y | 1 |
| Hao, J | 2 |
| Du, Y | 1 |
| Ning, J | 1 |
| Wang, K | 1 |
| Shao, Y | 1 |
| Cheng, X | 1 |
| Yan, Z | 1 |
1 trial available for fp 83 and Neoplasms
| Article | Year |
|---|---|
Intravenous flurbiprofen axetil enhances analgesic effect of opioids in patients with refractory cancer pain by increasing plasma β-endorphin.
Topics: Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; beta-Endorphin; Drug Synergism; Drug Th | 2014 |
2 other studies available for fp 83 and Neoplasms
| Article | Year |
|---|---|
Intravenous flurbiprofen axetil can increase analgesic effect in refractory cancer pain.
Topics: Analgesia; Female; Flurbiprofen; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasms; Pain | 2009 |
Intravenous flurbiprofen axetil to relieve cancer-related multiple breakthrough pain: a clinical study.
Topics: Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Breakthrough Pain; Case-Control Studies | 2013 |